Analysis of Long-term (Investment) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Allergan PLC, long-term (investment) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Allergan PLC net fixed asset turnover ratio deteriorated from Q3 2019 to Q4 2019 but then slightly improved from Q4 2019 to Q1 2020. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Allergan PLC net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 not reaching Q3 2019 level. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Allergan PLC total asset turnover ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Allergan PLC equity turnover ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020. |
Net Fixed Asset Turnover
Allergan PLC, net fixed asset turnover calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Net revenues | 3,604,400) | 4,351,000) | 4,050,700) | 4,090,100) | 3,597,100) | 4,079,700) | 3,911,400) | 4,124,200) | 3,672,100) | 4,326,100) | 4,034,300) | 4,007,400) | 3,572,900) | 3,864,300) | 3,622,200) | 3,684,800) | 3,399,300) | 2,664,500) | 4,088,900) | 5,755,000) | 2,562,600) | |||||||
| Property, plant and equipment, net | 1,915,400) | 1,926,500) | 1,857,000) | 1,821,000) | 1,781,100) | 1,787,000) | 1,756,600) | 1,761,400) | 1,769,500) | 1,785,400) | 1,802,200) | 1,750,100) | 1,659,300) | 1,611,300) | 1,566,300) | 1,557,200) | 1,602,400) | 1,573,900) | 1,569,900) | 2,859,000) | 2,797,900) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||
| Net fixed asset turnover1 | 8.40 | 8.35 | 8.52 | 8.61 | 8.82 | 8.83 | 9.13 | 9.17 | 9.06 | 8.93 | 8.59 | 8.61 | 8.89 | 9.04 | 8.54 | 8.89 | 9.93 | 9.58 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 11.50 | 11.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 4.68 | 4.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 5.07 | 4.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 2.92 | 2.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 4.90 | 4.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 4.75 | 4.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 3.15 | 3.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 3.47 | 3.71 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 2.71 | 2.72 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 5.42 | 5.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Net fixed asset turnover
= (Net revenuesQ1 2020
+ Net revenuesQ4 2019
+ Net revenuesQ3 2019
+ Net revenuesQ2 2019)
÷ Property, plant and equipment, net
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100)
÷ 1,915,400 = 8.40
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Allergan PLC net fixed asset turnover ratio deteriorated from Q3 2019 to Q4 2019 but then slightly improved from Q4 2019 to Q1 2020. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Allergan PLC, net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (Net revenuesQ1 2020
+ Net revenuesQ4 2019
+ Net revenuesQ3 2019
+ Net revenuesQ2 2019)
÷ Property, plant and equipment, net (including operating lease, right-of-use asset)
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100)
÷ 2,396,400 = 6.72
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Allergan PLC net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 not reaching Q3 2019 level. |
Total Asset Turnover
Allergan PLC, total asset turnover calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Net revenues | 3,604,400) | 4,351,000) | 4,050,700) | 4,090,100) | 3,597,100) | 4,079,700) | 3,911,400) | 4,124,200) | 3,672,100) | 4,326,100) | 4,034,300) | 4,007,400) | 3,572,900) | 3,864,300) | 3,622,200) | 3,684,800) | 3,399,300) | 2,664,500) | 4,088,900) | 5,755,000) | 2,562,600) | |||||||
| Total assets | 88,426,200) | 94,699,100) | 94,408,900) | 95,480,700) | 98,036,300) | 101,787,600) | 106,542,500) | 108,858,800) | 112,021,300) | 118,341,900) | 118,992,800) | 124,734,800) | 126,836,900) | 128,986,300) | 143,607,700) | 132,619,100) | 136,073,700) | 135,840,700) | 142,816,300) | 138,411,100) | 139,460,700) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||
| Total asset turnover1 | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | 0.16 | 0.15 | 0.15 | 0.14 | 0.13 | 0.13 | 0.12 | 0.12 | 0.11 | 0.09 | 0.10 | 0.12 | 0.11 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 0.37 | 0.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.37 | 0.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.24 | 0.20 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.56 | 0.57 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.37 | 0.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.53 | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.57 | 0.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.29 | 0.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.51 | 0.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.44 | 0.44 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Total asset turnover
= (Net revenuesQ1 2020
+ Net revenuesQ4 2019
+ Net revenuesQ3 2019
+ Net revenuesQ2 2019)
÷ Total assets
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100)
÷ 88,426,200 = 0.18
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Allergan PLC total asset turnover ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020. |
Equity Turnover
Allergan PLC, equity turnover calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Net revenues | 3,604,400) | 4,351,000) | 4,050,700) | 4,090,100) | 3,597,100) | 4,079,700) | 3,911,400) | 4,124,200) | 3,672,100) | 4,326,100) | 4,034,300) | 4,007,400) | 3,572,900) | 3,864,300) | 3,622,200) | 3,684,800) | 3,399,300) | 2,664,500) | 4,088,900) | 5,755,000) | 2,562,600) | |||||||
| Shareholders’ equity | 57,997,700) | 58,173,600) | 58,475,200) | 59,674,700) | 61,542,000) | 65,114,100) | 70,507,800) | 71,243,500) | 72,327,900) | 73,821,100) | 71,159,400) | 75,220,400) | 75,188,400) | 76,192,700) | 89,725,900) | 76,643,900) | 77,450,000) | 76,591,400) | 77,473,700) | 72,069,100) | 71,404,800) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||
| Equity turnover1 | 0.28 | 0.28 | 0.27 | 0.26 | 0.26 | 0.24 | 0.23 | 0.23 | 0.22 | 0.22 | 0.22 | 0.20 | 0.20 | 0.19 | 0.15 | 0.18 | 0.21 | 0.20 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 2.41 | 2.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.62 | 0.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 7.50 | 8.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.01 | 0.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 1.35 | 1.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 1.83 | 1.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.75 | 0.82 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.66 | 0.71 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.90 | 0.86 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Equity turnover
= (Net revenuesQ1 2020
+ Net revenuesQ4 2019
+ Net revenuesQ3 2019
+ Net revenuesQ2 2019)
÷ Shareholders’ equity
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100)
÷ 57,997,700 = 0.28
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Allergan PLC equity turnover ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020. |